Understanding and overcoming resistance to PARP inhibitors in cancer therapy
The DOI matches its Crossref record; 265 of the 265 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–265 of 265
Hypoxia-Induced Epigenetic Regulation and Silencing of the BRCA1 Promoter
Lu, Y., Chu, A., Turker, M. S., & Glazer, P. M. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01121-10 · Cited by 134
The rise and fall of poly(ADP-ribose): An enzymatic perspective
Pascal, J. M., & Ellenberger, T. (2015) · DNA repair · doi:10.1016/j.dnarep.2015.04.008 · Cited by 132
53BP1 Enforces Distinct Pre- and Post-resection Blocks on Homologous Recombination
Callén, E., Zong, D., Wu, W., Wong, N., Stanlie, A., Ishikawa, M., Pavani, R., Dumitrache, L. C., Byrum, A. K., Mendez‐Dorantes, C., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.024 · Cited by 132
Lai, X., Broderick, R., Bergoglio, V., Zimmer, J., Badie, S., Niedźwiedź, W., Hoffmann, J., & Tarsounas, M. (2017) · Nature Communications · doi:10.1038/ncomms15983 · Cited by 124
PARP Trapping Beyond Homologous Recombination and Platinum Sensitivity in Cancers
Murai, J., & Pommier, Y. G. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055914 · Cited by 120
CtIP-mediated resection is essential for viability and can operate independently of BRCA1
Polato, F., Callen, E., Wong, N., Faryabi, R., Bunting, S., Chen, H.-T., Kozak, M., Kruhlak, M. J., Reczek, C. R., Lee, W.-H., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131939 · Cited by 116
BRCA1 Haploinsufficiency Is Masked by RNF168-Mediated Chromatin Ubiquitylation
Zong, D., Adam, S., Wang, Y., Sasanuma, H., Callén, E., Murga, M., Day, A., Kruhlak, M. J., Wong, N., Munro, M., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.12.010 · Cited by 116
Friedlander, M., Meniawy, T., Markman, B., Mileshkin, L., Harnett, P., Millward, M., Lundy, J., Freimund, A., Norris, C., Mu, S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30396-1 · Cited by 116
Konstantinopoulos, P. A., Wilson, A. J., Saskowski, J., Wass, E., & Khabele, D. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.03.007 · Cited by 115
Proteomic analyses identify ARH3 as a serine mono-ADP-ribosylhydrolase
Abplanalp, J., Leutert, M., Frugier, E., Nowak, K., Feurer, R., Kato, J., Kistemaker, H. V. A., Filippov, D. V., Moss, J., Caflisch, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02253-1 · Cited by 115
Michelena, J., Lezaja, A., Teloni, F., Schmid, T., Imhof, R., & Altmeyer, M. (2018) · Nature Communications · doi:10.1038/s41467-018-05031-9 · Cited by 115
Treszezamsky, A. D., Kachnic, L. A., Feng, Z., Zhang, J., Tokadjian, C., & Powell, S. N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0601 · Cited by 113
Wang, L., Yang, C., Xie, C., Jiang, J., Gao, M., Li, F., Li, Y., Bao, X., Fu, H., & Lou, L. (2019) · Cancer Science · doi:10.1111/cas.13947 · Cited by 113
Mueller-Dieckmann, C., Kernstock, S., Lisurek, M., von Kries, J. P., Haag, F., Weiss, M. S., & Koch-Nolte, F. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606762103 · Cited by 112
FAM35A associates with REV7 and modulates DNA damage responses of normal and BRCA1‐defective cells
Tomida, J., Takata, K., Bhetawal, S., Person, M. D., Chao, H., Tang, D. G., & Wood, R. D. (2018) · The EMBO Journal · doi:10.15252/embj.201899543 · Cited by 111
Becker, J. R., Cuella-Martin, R., Barazas, M., Liu, R., Oliveira, C., Oliver, A. W., Bilham, K., Holt, A. B., Blackford, A. N., Heierhorst, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07855-x · Cited by 110
Self-citationNacson, J., Krais, J. J., Bernhardy, A. J., Clausen, E., Feng, W., Wang, Y., Nicolas, É., Cai, K. Q., Tricarico, R., Hua, X., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.086 · Cited by 108
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment
Wheeler, D. A., Takebe, N., Hinoue, T., Hoadley, K. A., Cardenas, M., Hamilton, A. M., Laird, P. W., Wang, L., Johnson, A., Dewal, N., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.10.015 · Cited by 108
Target engagement imaging of PARP inhibitors in small-cell lung cancer
Carney, B. D., Kossatz, S., Lok, B. H., Schneeberger, V. E., Gangangari, K. K., Pillarsetty, N., Weber, W., Rudin, C. M., Poirier, J. T., & Reiner, T. (2018) · Nature Communications · doi:10.1038/s41467-017-02096-w · Cited by 107
Schoonen, P. M., Talens, F., Stok, C., Gogola, E., Heijink, A. M., Bouwman, P., Foijer, F., Tarsounas, M., Blatter, S., Jonkers, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms15981 · Cited by 104
Self-citationNagashima, H., Lee, C. K., Tateishi, K., Higuchi, F., Subramanian, M. P., Rafferty, S., Melamed, L., Miller, J. J., Wakimoto, H., & Cahill, D. P. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0226 · Cited by 103
Xiong, Y., Guo, Y., Liu, Y., Wang, H., Gong, W., Liu, Y., Wang, X., Gao, Y., Yu, F., Su, D., et al. (2020) · Neoplasia · doi:10.1016/j.neo.2020.06.009 · Cited by 102
Sullivan-Reed, K., Bolton-Gillespie, E., Dasgupta, Y., Langer, S. K., Siciliano, M., Nieborowska-Skorska, M., Hanamshet, K., Belyaeva, E. A., Bernhardy, A. J., Lee, J. W., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.034 · Cited by 99
An OB-fold complex controls the repair pathways for DNA double-strand breaks
Gao, S., Feng, S., Ning, S., Liu, J., Zhao, H., Xu, Y., Shang, J., Li, K., Li, Q., Guo, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06407-7 · Cited by 98
Synergistic Loss of Prostate Cancer Cell Viability by Coinhibition of HDAC and PARP
Chao, O. S., & Goodman, O. B. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0173 · Cited by 92
RAD52 Prevents Excessive Replication Fork Reversal and Protects from Nascent Strand Degradation
Malacaria, E., Pugliese, G. M., Honda, M., Marabitti, V., Aiello, F. A., Spies, M., Franchitto, A., & Pichierri, P. (2018) · Nature Communications · doi:10.1038/s41467-019-09196-9 · Cited by 92
CHFR is important for the first wave of ubiquitination at DNA damage sites
Liu, C., Wu, J., Paudyal, S. C., You, Z., & Yu, X. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1278 · Cited by 91
Warfe, D. M., Jardine, T. D., Pettit, N. E., Hamilton, S. K., Pusey, B. J., Bunn, S. E., Davies, P. M., & Douglas, M. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066240 · Cited by 91
Kizilbash, S. H., Gupta, S. K., Chang, K., Kawashima, R., Parrish, K. E., Carlson, B. L., Bakken, K. K., Mladek, A. C., Schroeder, M. A., Decker, P. A., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0365 · Cited by 90
Luijsterburg, M. S., Typas, D., Caron, M.-C., Wiegant, W. W., Heuvel, D. V. D., Boonen, R. A., Couturier, A. M., Mullenders, L. H., Masson, J.-Y., & van Attikum, H. (2017) · eLife · doi:10.7554/elife.20922 · Cited by 89
PARP3 is a sensor of nicked nucleosomes and monoribosylates histone H2BGlu2
Grundy, G. J., Polo, L. M., Zeng, Z., Rulten, S. L., Hoch, N. C., Paomephan, P., Xu, Y., Sweet, S. M., Thorne, A. W., Oliver, A. W., et al. (2016) · Nature Communications · doi:10.1038/ncomms12404 · Cited by 87
Pishvaian, M. J., Biankin, A. V., Bailey, P. J., Chang, D. K.-F., Laheru, D. A., Wolfgang, C. L., & Brody, J. R. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.40 · Cited by 85
BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug Resistance
Jaspers, J. E., Sol, W., Kersbergen, A. J., Schlicker, A., Guyader, C., Xu, G., Wessels, L. F. A., Borst, P., Jonkers, J., & Rottenberg, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-0839 · Cited by 82
Self-citationReczek, C. R., Szabolcs, M., Stark, J. M., Ludwig, T., & Baer, R. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201302145 · Cited by 81
Afghahi, A., Timms, K. M., Vinayak, S., Jensen, K. C., Kurian, A. W., Carlson, R. W., Chang, P.-J., Schackmann, E. A., Hartman, A., Ford, J. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2174 · Cited by 81
Evers, B., Schut, E., van der Burg, E., Braumuller, T. M., Egan, D. A., Holstege, H., Edser, P., Adams, D. J., Wade-Martins, R., Bouwman, P., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2434 · Cited by 80
Self-citationMarijon, H., Lee, D. H., Ding, L., Sun, H., Gery, S., de Gramont, A., & Koeffler, H. P. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.01.045 · Cited by 77
NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression
Bian, C., Zhang, C., Luo, T., Vyas, A., Chen, S.-H., Liu, C., Kassab, M. A., Yang, Y., Kong, M., & Yu, X. (2019) · Nature Communications · doi:10.1038/s41467-019-08530-5 · Cited by 72
Poveda, A., Floquet, A., Ledermann, J. A., Asher, R., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Pignata, S., Friedlander, M., et al. (2021) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000962 · Cited by 68
Belotserkovskaya, R., Gil, E. R., Lawrence, N., Butler, R., Clifford, G., Wilson, M. D., & Jackson, S. P. (2020) · Nature Communications · doi:10.1038/s41467-020-14563-y · Cited by 66
Parrotta, R., Okonska, A., Ronner, M., Weder, W., Stahel, R., Penengo, L., & Felley-Bosco, E. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.03.023 · Cited by 65
Banerjee, S. N., Moore, K. N., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M. L., Lisyanskaya, A. S., Floquet, A., Leary, A. F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.950 · Cited by 65
RNF8 Regulates Assembly of RAD51 at DNA Double-Strand Breaks in the Absence of BRCA1 and 53BP1
Nakada, S., Yonamine, R. M., & Matsuo, K. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1057 · Cited by 64
Choi, Y. E., Battelli, C., Watson, J., Liu, J. F., Curtis, J. D., Morse, A., Matulonis, U. A., Chowdhury, D., & Konstantinopoulos, P. A. (2014) · Oncotarget · doi:10.18632/oncotarget.1929 · Cited by 63
Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors
Barazas, M., Gasparini, A., Huang, Y., Küçükosmanoğlu, A., Annunziato, S., Bouwman, P., Sol, W., Kersbergen, A. J., Proost, N., de Korte‐Grimmerink, R., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2077 · Cited by 62
Self-citationTung, N., Robson, M. E., Ventz, S., Santa-Maria, C. A., Marcom, P. K., Nanda, R., Shah, P. D., Ballinger, T. J., Yang, E. S.-H., Melisko, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.1002 · Cited by 60
Daniel, R. A., Rozanska, A. L., Mulligan, E. A., Drew, Y., Thomas, H. D., Castelbuono, D. J., Hostomský, Z., Plummer, E. R., Tweddle, D. A., Boddy, A. V., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605946 · Cited by 57
Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence
Brasky, T. M., Felix, A. S., Cohn, D. E., McMeekin, D. S., Mutch, D. G., Creasman, W. T., Thaker, P. H., Walker, J. L., Moore, R. G., Lele, S., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw251 · Cited by 56
Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End Joining
Francica, P., Mutlu, M., Blomen, V. A., Oliveira, C., Nowicka, Z., Trenner, A., Gerhards, N. M., Bouwman, P., Stickel, E., Hekkelman, M. L., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108068 · Cited by 55
Self-citationPoly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide
Tentori, L., Leonetti, C., Scarsella, M., Muzi, A., Vergati, M., Forini, O., Lacal, P. M., Ruffini, F., Gold, B. I., Li, W., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.027 · Cited by 51
Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions
Domchek, S. M. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0734 · Cited by 51
Vidula, N., Rich, T. A., Sartor, O. A., Yen, J. L., Hardin, A. I., Nance, T., Lilly, M. B., Nezami, M. A., Patel, S. P., Carneiro, B. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2933 · Cited by 51
Feng, F. Y.-C., Speers, C. W., Liu, M., Jackson, W., Moon, D. H., Rinkinen, J. R., Wilder-Romans, K., Jagsi, R., & Pierce, L. J. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3085-5 · Cited by 42
53BP1/RIF1 signaling promotes cell survival after multifractionated radiotherapy
Eke, I., Zong, D., Aryankalayil, M. J., Sandfort, V., Bylicky, M. A., Rath, B. H., Graves, E. E., Nussenzweig, A., & Coleman, C. N. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1139 · Cited by 40
Jiang, J., Lu, Y., Li, Z., Li, L., Niu, D.-L., Xu, W., Liu, J., Fu, L. N., Zhou, Z., Gu, Y., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-016-0424-x · Cited by 35
Halford, S. E. R., Cruickshank, G. S., Dunn, L., Erridge, S., Godfrey, L. M., Herbert, C. E., Jefferies, S., Lopez, J. S., McBain, C. A., Pittman, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.2022 · Cited by 33
Kristeleit, R. S., Shapira‐Frommer, R., Oaknin, A., Balmañà, J., Ray-Coquard, I., Domchek, S. M., Tinker, A. V., Castro, C. M., Welch, S. A., Poveda, A. M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw374.03 · Cited by 30
Moore, K. N., Secord, A. A., Geller, M. A., Miller, D. S., Cloven, N. G., Fleming, G. F., Hendrickson, A. E. W., Azodi, M., DiSilvestro, P., Oza, A. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.5514 · Cited by 29
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
Hodgson, D., Dougherty, B. A., Lai, Z., Grinsted, L. M., Spencer, S., O’Connor, M. J., Ho, T. W., Robertson, J. D., Lanchbury, J. S. S., Timms, K., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)30269-6 · Cited by 26
Pothuri, B., Brodsky, A. L., Sparano, J. A., Blank, S. V., Kim, M., Hershman, D. L., Tiersten, A., Kiesel, B. F., Beumer, J. H., Liebes, L., et al. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04030-2 · Cited by 25
Werner, T. L., Sachdev, J. C., Swisher, E. M., Gutiérrez, M., Kittaneh, M., Stein, M. N., Xiong, H., Dunbar, M., Sullivan, D. M., Komarnitsky, P. B., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1488 · Cited by 20
With great power comes great vulnerability
de Oliveira, R. L., Wang, L., & Bernards, R. (2018) · Molecular & Cellular Oncology · doi:10.1080/23723556.2018.1509488 · Cited by 5
Ganesan, S., & Garber, J. E. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00269 · Cited by 5
Self-citationMolecular Profiling for Proper Diagnosis of Gastroenteropancreatic Neuroendocrine Tumor
Serei, V. D., Poplin, E. A., Ganesan, S., & Riedlinger, G. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00111 · Cited by 2
Self-citationFriedlander, M. L., Moore, K. N., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Lisyanskaya, A. S., Floquet, A., Leary, A. F., Sonke, G. S., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.228 · Cited by 2
Cited by
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Abuetabh, Y., Wu, H. H., Chai, C., Al Yousef, H., Persad, S., Sergi, C. M., & Leng, R. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00863-4 · Cited by 272
Drug resistance in ovarian cancer: from mechanism to clinical trial
Wang, L., Wang, X., Zhu, X., Zhong, L., Jiang, Q., Wang, Y., Tang, Q., Li, Q., Zhang, C., Wang, H., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01967-3 · Cited by 255
Sun, L., Liu, Y., Guo, X., Cui, T., Wu, C., Tao, J., Cheng, C., Chu, Q., Ji, C., Li, X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49573-7 · Cited by 18
“PARPi impedes tumorigenesis by blocking PARP1 at the site of DNA lesions, inducing DNA-protein crosslinks that trigger replication fork collapse, and subsequently accumulate DSBs during S-phase in the cell cycle 15,25 – 27 .”
Metadata
- Authors
- Dias, M. P., Moser, S. C., Ganesan, S., & Jonkers, J.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2021-07-20
- Volume
- 18
- Issue
- 12
- Pages
- 773-791
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W3184202385
- Cited by
- 505
- References
- 265
- FWCI
- 12.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.